Ronald I Eisenstein

Partner at Nixon Peabody LLP

Ronald I Eisenstein focuses his practice on advising biotechnology and pharmaceutical companies, research institutes and universities on patent portfolio management, post-issuance strategies, dispute management and due diligence. He is also a member of Nixon Peabody’s life sciences team.

Leveraging his scientific background, extensive legal experience and business acumen, Mr Eisenstein strategically counsels clients on upcoming legal and business trends. He focuses his practice in the life sciences sector where he provides patent prosecution, interferences, oppositions, client counselling, transactional matters, due diligence and patent litigation services. He represents major US research institutions, US companies and foreign corporations in interferences before the USPTO, which have involved immune modulation including antibodies; gene therapy; cancer vaccines; angiogenesis modulation; personalised medicine, including diagnostics, proteomics, biomarkers, companion diagnostics and related systems; synthetic biology; small molecules; magnetic resonance imaging; and primate lentiviruses.

Mr Eisenstein has extensive experience in prosecuting biotechnology, medical, and chemical cases, and counselling with respect to strategic management of IP portfolios, including due diligence and evaluation of portfolios held by third parties and responses to infringement and validity opinions, acquisitions and strategic use of oppositions.

Additionally, Mr Eisenstein helps clients understand and effectively use post-issuance procedures such as oppositions, interferences and inter partes reviews – both offensively and defensively. He also provides freedom-to-operate guidance to clients, as well as due diligence for acquisitions and financing.

Firm details

Nixon Peabody LLP
Exchange Place
53 State Street
Boston MA 02109- 2835
United States

Contact details

See firm profile